GeneDx Holdings Corp. Class A (WGS) Dividend History

Company News

• VRA Investor News: If You Have Suffered Losses in Vera Bradley, Inc. (NASDAQ: VRA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

  Rosen Law Firm is investigating potential securities claims for Vera Bradley shareholders after the company reported disappointing first quarter financial results, causing a 19% stock price drop.

  GlobeNewswire Inc.

  Featured Companies: RCKT VRA
• WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm

  The Schall Law Firm is investigating claims on behalf of investors of GeneDx Holdings Corp. for potential violations of securities laws, focusing on whether the company issued false or misleading statements.

  Benzinga
• Why GeneDx Holdings Stock Is Plunging Today

  GeneDx Holdings (WGS) stock plunged 42.9% despite reporting better-than-expected Q1 revenue and earnings. Investors were disappointed by the smaller-than-usual revenue beat and a decline in test volume. The company raised its full-year revenue guidance, but its valuation appears expensive compared to industry peers.

  The Motley Fool
• GeneDx Stock Was up 2,700% in 2024 — Can It Keep Rising?

  GeneDx, a leader in genome and exome testing, saw its stock price surge over 2,700% in 2024. The company's strong earnings and revenue growth in Q4 2024 have continued into 2025, with the stock price spiking 47% on Tuesday. However, a recent negative report by Grizzly Research has raised concerns about the company's growth.

  Investing.com
• GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates

  GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 51.47% and 25.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: PGNY